We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Devicemakers that want the cost of their products reimbursed by the Centers for Medicare & Medicaid Services (CMS) for Phase I or II clinical trials must make sure their studies clearly indicate therapeutic intent and fit into a specific category.